Mark Bagnall, CEO of Phenomix Sciences, expressed enthusiasm about the new partnerships: 'As leaders in their respective fields of lab testing and patient empowerment, we are excited to add DexCom and Labcorp as investors as we continue to scale our company.'
Phenomix Sciences aims to use the funding to accelerate the commercialization and adoption of its MyPhenome test which categorizes patients into obesity phenotypes, helping physicians develop effective treatment plans.
The funds will also support the development of additional phenotyping tests, ongoing clinical studies, patenting novel insights, and establishing strategic partnerships with pharmaceutical companies and healthcare providers.
The SBIR grant will enable Phenomix Sciences to conduct further clinical studies to demonstrate the value of precision medicine in obesity treatment, highlighting the importance of the company's work.
[
add
]
[
|
|
...
]